These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 23419317

  • 1. Thrombin inhibits osteoclast differentiation through a non-proteolytic mechanism.
    Sivagurunathan S, Pagel CN, Loh LH, Wijeyewickrema LC, Pike RN, Mackie EJ.
    J Mol Endocrinol; 2013 Jun; 50(3):347-59. PubMed ID: 23419317
    [Abstract] [Full Text] [Related]

  • 2. Activation of protease-activated receptor-2 leads to inhibition of osteoclast differentiation.
    Smith R, Ransjö M, Tatarczuch L, Song SJ, Pagel C, Morrison JR, Pike RN, Mackie EJ.
    J Bone Miner Res; 2004 Mar; 19(3):507-16. PubMed ID: 15040840
    [Abstract] [Full Text] [Related]

  • 3. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D, Katagiri M, Ogasawara T, Ogata N, Shimoaka T, Takato T, Nakamura K, Kawaguchi H.
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [Abstract] [Full Text] [Related]

  • 4. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
    Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ.
    J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
    [Abstract] [Full Text] [Related]

  • 5. Dual modulation of osteoclast differentiation by lipopolysaccharide.
    Zou W, Bar-Shavit Z.
    J Bone Miner Res; 2002 Jul; 17(7):1211-8. PubMed ID: 12096834
    [Abstract] [Full Text] [Related]

  • 6. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    Quinn JM, Itoh K, Udagawa N, Hausler K, Yasuda H, Shima N, Mizuno A, Higashio K, Takahashi N, Suda T, Martin TJ, Gillespie MT.
    J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
    [Abstract] [Full Text] [Related]

  • 7. High extracellular Ca2+ alone stimulates osteoclast formation but inhibits in the presence of other osteoclastogenic factors.
    Shin MM, Kim YH, Kim SN, Kim GS, Baek JH.
    Exp Mol Med; 2003 Jun 30; 35(3):167-74. PubMed ID: 12858015
    [Abstract] [Full Text] [Related]

  • 8. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.
    Biochem Pharmacol; 2013 Sep 15; 86(6):782-90. PubMed ID: 23928189
    [Abstract] [Full Text] [Related]

  • 9. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
    Chung YH, Chang EJ, Kim SJ, Kim HH, Kim HM, Lee SB, Ko JS.
    J Periodontal Res; 2006 Aug 15; 41(4):288-96. PubMed ID: 16827722
    [Abstract] [Full Text] [Related]

  • 10. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
    Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD, Liao EY.
    J Bone Miner Res; 2006 Oct 15; 21(10):1648-56. PubMed ID: 16995820
    [Abstract] [Full Text] [Related]

  • 11. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH.
    Mol Pharmacol; 2010 Jan 15; 77(1):17-25. PubMed ID: 19828731
    [Abstract] [Full Text] [Related]

  • 12. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S, Liu XS, Huang S, Li Z, Pan H, Zhen W, Luk KD, Guo XE, Lu WW.
    Bone; 2011 Dec 15; 49(6):1290-8. PubMed ID: 21925296
    [Abstract] [Full Text] [Related]

  • 13. Interleukin-17A stimulates granulocyte-macrophage colony-stimulating factor release by murine osteoblasts in the presence of 1,25-dihydroxyvitamin D(3) and inhibits murine osteoclast development in vitro.
    Balani D, Aeberli D, Hofstetter W, Seitz M.
    Arthritis Rheum; 2013 Feb 15; 65(2):436-46. PubMed ID: 23124514
    [Abstract] [Full Text] [Related]

  • 14. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
    Kanatani M, Sugimoto T, Kano J, Kanzawa M, Chihara K.
    J Cell Physiol; 2003 Jul 15; 196(1):180-9. PubMed ID: 12767054
    [Abstract] [Full Text] [Related]

  • 15. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K, Udagawa N, Matsuzaki K, Takami M, Amano H, Shinki T, Ueno Y, Takahashi N, Suda T.
    J Bone Miner Res; 2000 Sep 15; 15(9):1766-75. PubMed ID: 10976996
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
    Shalhoub V, Faust J, Boyle WJ, Dunstan CR, Kelley M, Kaufman S, Scully S, Van G, Lacey DL.
    J Cell Biochem; 1999 Feb 01; 72(2):251-61. PubMed ID: 10022507
    [Abstract] [Full Text] [Related]

  • 19. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin.
    Shiotani A, Takami M, Itoh K, Shibasaki Y, Sasaki T.
    Anat Rec; 2002 Oct 01; 268(2):137-46. PubMed ID: 12221720
    [Abstract] [Full Text] [Related]

  • 20. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
    Kim HN, Ha H, Lee JH, Jung K, Yang D, Woo KM, Lee ZH.
    Eur J Pharmacol; 2009 Nov 25; 623(1-3):22-9. PubMed ID: 19766111
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.